Table 1.
The IC50 value of compounds (7a-7 m) and PTX against hTS enzyme and five cancer cell lines.
| Compounds | IC50a(µM) |
|||||
|---|---|---|---|---|---|---|
| hTS | A549b | OVCAR-3c | SGC7901d | MCF-7e | HepG2f | |
| 7a | 3.15 ± 0.61 | 7.80 ± 0.22 | 6.03 ± 0.47 | >10 | 7.38 ± 0.49 | >10 |
| 7b | 2.75 ± 0.29 | 5.33 ± 0.14 | 5.91 ± 0.94 | 7.00 ± 0.28 | 5.24 ± 0.73 | 5.78 ± 0.55 |
| 7c | 1.46 ± 0.37 | 3.23 ± 0.11 | 5.06 ± 0.22 | 5.63 ± 0.07 | 5.11 ± 1.27 | 3.43 ± 0.21 |
| 7d | 1.79 ± 0.12 | 5.73 ± 0.10 | 5.63 ± 0.07 | 6.71 ± 0.10 | 5.74 ± 0.81 | 4.71 ± 0.59 |
| 7e | 0.65 ± 0.43 | 1.37 ± 0.12 | 2.47 ± 0.26 | 2.61 ± 0.17 | 2.49 ± 0.04 | 3.61 ± 0.22 |
| 7f | 0.11 ± 0.03 | 0.78 ± 0.07 | 1.09 ± 0.18 | 1.26 ± 0.17 | 1.55 ± 0.06 | 2.06 ± 0.31 |
| 7 g | 0.44 ± 0.10 | 1.08 ± 0.12 | 1.66 ± 0.21 | 1.65 ± 0.11 | 1.93 ± 0.17 | 2.75 ± 0.15 |
| 7 h | 5.18 ± 0.73 | 7.35 ± 0.19 | 9.36 ± 0.14 | 9.77 ± 0.19 | 8.24 ± 1.27 | >10 |
| 7i | 4.61 ± 1.10 | 6.12 ± 0.61 | 8.03 ± 0.39 | 8.17 ± 0.96 | 8.11 ± 1.03 | 8.24 ± 1.27 |
| 7j | 5.61 ± 0.60 | 9.66 ± 1.02 | 8.75 ± 0.49 | 9.84 ± 0.63 | 9.84 ± 0.63 | >10 |
| 7 k | 1.16 ± 0.37 | 1.91 ± 0.08 | 4.02 ± 0.85 | 4.28 ± 0.62 | 4.15 ± 0.32 | 5.15 ± 0.20 |
| 7 l | 0.93 ± 0.28 | 1.15 ± 0.08 | 2.86 ± 0.87 | 2.47 ± 0.09 | 2.29 ± 0.55 | 4.38 ± 0.43 |
| 7 m | 1.29 ± 0.12 | 1.87 ± 0.12 | 3.74 ± 0.16 | 4.60 ± 0.16 | 5.57 ± 0.48 | 4.96 ± 0.59 |
| PTX | 2.44 ± 0.88 | 3.29 ± 0.15 | 5.35 ± 0.60 | 6.96 ± 0.43 | 4.18 ± 0.14 | 3.73 ± 0.31 |
a: IC50 = Mean ± SD, after 24 h of treatment. The values were average from at least 3 independent experiments.
b: Human lung cancer cell lines.
c: Human ovarian cancer cell lines.
d: Human gastric cancer cell lines.
e: Human breast cancer cell lines.
f: Human liver cancer cell lines.